Investment Centers of America Inc. Takes Position in GW Pharmaceuticals PLC (GWPH)
Investment Centers of America Inc. bought a new stake in GW Pharmaceuticals PLC (NASDAQ:GWPH) during the second quarter, according to the company in its most recent disclosure with the SEC. The firm bought 4,193 shares of the biopharmaceutical company’s stock, valued at approximately $420,000.
Several other hedge funds have also modified their holdings of GWPH. BNP Paribas Arbitrage SA acquired a new stake in shares of GW Pharmaceuticals PLC in the 2nd quarter valued at $163,000. Quantitative Systematic Strategies LLC acquired a new stake in shares of GW Pharmaceuticals PLC during the 2nd quarter valued at $204,000. Blair William & Co. IL acquired a new stake in shares of GW Pharmaceuticals PLC during the 1st quarter valued at $207,000. Ameriprise Financial Inc. boosted its holdings in shares of GW Pharmaceuticals PLC by 8.5% during the 2nd quarter. Ameriprise Financial Inc. now owns 2,064 shares of the biopharmaceutical company’s stock valued at $207,000 after acquiring an additional 162 shares in the last quarter. Finally, Cambridge Investment Research Advisors Inc. acquired a new stake in shares of GW Pharmaceuticals PLC during the 2nd quarter valued at $213,000. 75.06% of the stock is currently owned by hedge funds and other institutional investors.
GW Pharmaceuticals PLC (NASDAQ GWPH) opened at 108.23 on Monday. GW Pharmaceuticals PLC has a one year low of $92.65 and a one year high of $137.88. The firm’s market capitalization is $2.74 billion. The firm’s 50-day moving average price is $105.92 and its 200 day moving average price is $110.11.
GW Pharmaceuticals PLC (NASDAQ:GWPH) last posted its quarterly earnings results on Monday, August 7th. The biopharmaceutical company reported ($2.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.73) by ($0.34). GW Pharmaceuticals PLC had a negative net margin of 1,384.41% and a negative return on equity of 28.80%. The business had revenue of $3.14 million for the quarter, compared to analysts’ expectations of $2.10 million. During the same quarter in the previous year, the company earned ($0.05) earnings per share. On average, equities analysts anticipate that GW Pharmaceuticals PLC will post ($5.94) earnings per share for the current fiscal year.
Several equities research analysts recently weighed in on the company. Maxim Group downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating and set a $61.00 price objective on the stock. in a report on Tuesday, August 8th. BidaskClub downgraded GW Pharmaceuticals PLC from a “buy” rating to a “hold” rating in a report on Thursday, August 10th. Leerink Swann reissued an “outperform” rating and set a $160.00 price objective (down previously from $162.00) on shares of GW Pharmaceuticals PLC in a report on Thursday, August 10th. Cantor Fitzgerald set a $208.00 price objective on GW Pharmaceuticals PLC and gave the company a “buy” rating in a report on Tuesday, August 8th. Finally, Evercore ISI assumed coverage on GW Pharmaceuticals PLC in a report on Wednesday, August 16th. They set an “outperform” rating and a $154.00 price objective on the stock. Four equities research analysts have rated the stock with a hold rating, seven have assigned a buy rating and one has given a strong buy rating to the stock. GW Pharmaceuticals PLC has an average rating of “Buy” and an average target price of $148.55.
About GW Pharmaceuticals PLC
GW Pharmaceuticals plc is a biopharmaceutical company focused on developing and commercializing therapeutics from its cannabinoid product platform in a range of disease areas. The Company’s lead cannabinoid product candidate is Epidiolex, which is a liquid formulation of pure plant-derived cannabidiol (CBD).
Want to see what other hedge funds are holding GWPH? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for GW Pharmaceuticals PLC (NASDAQ:GWPH).
Receive News & Stock Ratings for GW Pharmaceuticals PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GW Pharmaceuticals PLC and related stocks with our FREE daily email newsletter.